financetom
Business
financetom
/
Business
/
Johnson & Johnson discontinues dengue drug study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Johnson & Johnson discontinues dengue drug study
Oct 4, 2024 8:18 AM

Oct 4 (Reuters) - Johnson & Johnson ( JNJ ) said on

Friday it will discontinue its mid-stage field study evaluating

the efficacy of its antiviral drug candidate for the prevention

of dengue.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
First Andes Silver Raises $1.01 Million in First Tranche of Private Placement
First Andes Silver Raises $1.01 Million in First Tranche of Private Placement
Jul 17, 2025
07:21 AM EDT, 07/17/2025 (MT Newswires) -- First Andes Silver ( MSLVF ) after markets closed on Wednesday said it closed the first tranche of its previously announced non-brokered private placement, raising about $1.01 million. The company issued 10.17 million units at $0.10 each. Each unit is made up of one common share of the company and one-half of one...
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Jul 17, 2025
July 17 (Reuters) - US drugmakers Bristol Myers and Pfizer ( PFE ) said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program. Eligible patients will be able to buy the drug directly through the Eliquis 360 Support program from September 8 at a rate that is...
Dryden Gold to Raise $7 Million Via Non-Brokered Equity Financing
Dryden Gold to Raise $7 Million Via Non-Brokered Equity Financing
Jul 17, 2025
07:19 AM EDT, 07/17/2025 (MT Newswires) -- Dryden Gold ( DRYGF ) on Thursday said it will raise up to $7 million through a non-brokered equity financing under the Listed Issuer Financing Exemption. The offering is comprised of flow-through common shares, charity flow-through shares and hard dollar shares. Proceeds of the financing will be used to expand the company's current...
Copyright 2023-2026 - www.financetom.com All Rights Reserved